1 – 10 of 18
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2020
- Plasma proteomics of biomarkers for inflammation or cancer cannot predict relapse in chronic myeloid leukaemia patients stopping tyrosine kinase inhibitor therapy
- 2019
- Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line
- 2018
- Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI) : a prespecified interim analysis of a prospective, multicentre, non-randomised, trial
- 2017
- No increased prevalence of malignancies among first-degree relatives of 800 patients with chronic myeloid leukemia : A population-based study in Sweden
- Advanced phase chronic myeloid leukaemia (CML) in the tyrosine kinase inhibitor era - a report from the Swedish CML register
-
Single-cell molecular analysis defines therapy response and immunophenotype of stem cell subpopulations in CML
Warfvinge, Rebecca LU ; Geironson Ulfsson, Linda LU ; Sommarin, Mikael N E LU ; Lang, Stefan LU
;
Karlsson, Christine
LU
;
Roschupkina, Teona
LU
;
Stenke, Leif
;
Stentoft, Jesper
;
Olsson-Strömberg, Ulla
and
Hjorth-Hansen, Henrik
, et al.
(2017)
In Blood
129(17).
p.2384-2394
Mark
- Tyrosine kinase inhibitor therapy-induced changes in humoral immunity in patients with chronic myeloid leukemia
- 2016
- Population-based assessment of chronic myeloid leukemia in Sweden: striking increase in survival and prevalence.
- Plasma proteomics in CML patients before and after initiation of tyrosine kinase inhibitor therapy reveals induced Th1 immunity and loss of angiogenic stimuli
- Cardiovascular events associated with use of tyrosine kinase inhibitors in chronic myeloid leukemia